BASCHI Quick Slimming capsules

Safety advisory

30 October 2015

BASCHI Quick Slimming capsules pose a serious risk to your health and should not be taken.

BASCHI quick slimming capsules pill packet

The Therapeutic Goods Administration (TGA) has tested a product labelled BASCHI Quick Slimming capsules and found that:

  • the capsules contain the undeclared substance sibutramine
  • consumers are advised that sibutramine is a prescription-only substance
  • Sibutramine was withdrawn from world markets in 2010 due to increased risk of cardiac events and stroke.

The supply of BASCHI Quick Slimming capsules is illegal.

BASCHI Quick Slimming capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia may have bought the product online.

Information for consumers

  • Stop taking BASCHI Quick Slimming capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of BASCHI Quick Slimming capsules from entering Australia.

If these capsules are found at the border by ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products
Email: (link sends e-mail)